Tg Therapeutics (TGTX) EBT Margin (2016 - 2025)
Historic EBT Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 16.02%.
- Tg Therapeutics' EBT Margin rose 109300.0% to 16.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.5%, marking a year-over-year increase of 217400.0%. This contributed to the annual value of 7.78% for FY2024, which is 21900.0% up from last year.
- According to the latest figures from Q3 2025, Tg Therapeutics' EBT Margin is 16.02%, which was up 109300.0% from 21.91% recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' EBT Margin peaked at 68.71% during Q3 2023, and registered a low of 100501.25% during Q4 2022.
- Moreover, its 5-year median value for EBT Margin was 296.19% (2023), whereas its average is 9240.29%.
- In the last 5 years, Tg Therapeutics' EBT Margin skyrocketed by 2000000000bps in 2021 and then tumbled by -964501500bps in 2022.
- Quarter analysis of 5 years shows Tg Therapeutics' EBT Margin stood at 4051.1% in 2021, then tumbled by -2381bps to 100501.25% in 2022, then soared by 100bps to 31.9% in 2023, then skyrocketed by 174bps to 23.53% in 2024, then crashed by -32bps to 16.02% in 2025.
- Its EBT Margin was 16.02% in Q3 2025, compared to 21.91% in Q2 2025 and 4.52% in Q1 2025.